Avenue Therapeutics Inc (NASDAQ:ATXI) saw a significant increase in short interest during the month of November. As of November 29th, there was short interest totalling 20,700 shares, an increase of 37.1% from the November 14th total of 15,100 shares. Approximately 0.3% of the company’s shares are short sold. Based on an average trading volume of 19,700 shares, the days-to-cover ratio is currently 1.1 days.
NASDAQ:ATXI traded up $0.82 on Thursday, reaching $7.63. The company’s stock had a trading volume of 3,000 shares, compared to its average volume of 16,142. Avenue Therapeutics has a 1-year low of $4.13 and a 1-year high of $7.98. The firm has a market cap of $102.13 million, a PE ratio of -3.64 and a beta of -0.43. The business’s 50-day moving average price is $5.84 and its two-hundred day moving average price is $5.89.
Avenue Therapeutics (NASDAQ:ATXI) last posted its quarterly earnings data on Monday, November 4th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.18. As a group, equities research analysts forecast that Avenue Therapeutics will post -1.66 earnings per share for the current fiscal year.
Separately, ValuEngine upgraded Avenue Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, November 15th.
Avenue Therapeutics Company Profile
Avenue Therapeutics, Inc, a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain.
Featured Story: Buy Rating
Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.